Medical policy: Diagnosis and Treatment of Dry Eye Syndrome

Número de política: MP 4.033

Fecha de entrada en vigor: 2/1/2026

Política

Eyelid thermal pulsation therapy, or intense pulsed light with subsequent meibomian gland expression to treat dry eye are considered investigational as a management of dry eye syndrome. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Near-infrared dual imaging of the meibomian glands is considered investigational. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Cross-references:

• MP 2.071 Nonpharmacologic Treatment of Rosacea

Variaciones del producto

Esta política solo se aplica a ciertos programas y productos administrados por Capital Blue Cross y está sujeta a variaciones en los beneficios. Consulte la información adicional a continuación.

FEP PPO - Consulte el Manual de Políticas Médicas de FEP.

Descripción/Antecedentes

Thermal pulsation is a treatment option for meibomian gland dysfunction. Meibomian gland dysfunction is recognized as the major cause of dry eye syndrome. Thermal pulsation applies heat to the palpebral surface of the upper and lower eyelids directly over the meibomian glands, while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands.

Dry eye syndrome

Dry eye syndrome (DES), dry eye disease, or dysfunctional tear syndrome, either alone or in combination with other conditions, is a frequent cause of ocular irritation that leads patients to seek ophthalmologic care. It is estimated to affect between 5% and 50% of the population worldwide. Based on data from 2013, an estimated 16.4 million Americans have dry eye syndrome. The prevalence of dry eye syndrome increases with age, especially in postmenopausal women. For both sexes, prevalence is more than 3 times higher in individuals 50 years of age or older compared to those 18 to 49 years of age. Meibomian gland dysfunction (MGD) is considered to be the most common cause of dry eye syndrome.

In a 2022 meta-analysis of three United States studies, the prevalence of dry eye ranged from 5% to 14% with an estimated pooled prevalence of 8%. The prevalence of meibomian gland dysfunction ranged from 10% to 55%. Over a 5-year period, the incidence of dry eye was 3% among individuals aged 18 and older and 8% among those aged 68 and older. Prevention and treatment of dry eye syndrome are expected to be of greater importance as the population ages.

Tratamiento

Current treatment options for meibomian gland dysfunction include physical expression to relieve the obstruction, administration of heat (warm compresses) to the eyelids to liquefy solidified meibomian gland contents, eyelid scrubs to relieve external meibomian gland orifice blockage, and medications (e.g., antibiotics, topical corticosteroids) to mitigate infection and inflammation of the eyelids. These treatment options, however, have shown limited clinical efficacy and often require a trial-and-error approach. For example, physical expression can be very painful given the amount of force needed to express obstructed glands. Warm compress therapy can be time-consuming and labor intensive, and there is limited evidence that medications relieve meibomian gland dysfunction.

While the symptoms of dry eye syndrome often improve with treatment, the disease usually is not curable and may lead to substantial patient and physician frustration. Dry eyes can be a cause of visual morbidity and may compromise results of corneal, cataract, and refractive surgery. Inadequate treatment of dry eye syndrome may result in increased ocular discomfort, blurred vision, reduced quality of life, and decreased productivity.

Thermal pulsation therapy is a relatively new therapy in management of dry eye syndrome resulting from meibomian gland dysfunction. Using a device such as the LipiFlow^® Thermal Pulsation System, the system delivers heat and pressure to the eyelids to assist in expressing blockages from clogged meibomian glands. Temperature and pressure are closely monitored during the procedure, and the system is designed to protect other delicate structures of the eye.

Intense pulsed light is another procedure in which wavelengths (550-1200 nm) of light are emitted over the eyelids, causing a warming effect. Often times, the procedure is followed by manual expression of the meibomian glands.

Recent research on these therapies, while somewhat minimal, has shown both safety and efficacy. Several studies have shown significant improvement in dry eye symptoms in the majority of patients receiving these therapies. Another study reveals that a single treatment with thermal pulsation therapy had similar effects in comparison to 3 months of standard treatment with twice daily warm compresses. While one study suggested intense pulsed light treatment provided benefit for up to 9 months, another study showed continued benefit from thermal pulsation treatment at a 3 year follow-up.

In a review and meta-analysis to investigate the efficacy and safety of a vectored thermal pulsation system in the treatment of dry eye disease resulting from Meibomian gland dysfunction (MGD), Hu et al. (2022) reviewed ten qualified RCTs incorporating 761 patients. The treatment was determined to improve the subjective and objective outcomes of MGD and did not increase the incidence of adverse events. The authors conclude

A Cochrane Review published in 2020 stated that the quality of evidence for safety and efficacy of intense pulsed light as a treatment for meibomian gland dysfunction was low or very low. The authors also noted a scarcity of randomized controlled trial evidence. Whether intense pulsed light is of value for modifying the symptoms or signs of evaporative dry eye disease is currently uncertain. While there are multiple randomized controlled trials currently in progress, the Cochrane review ultimately concluded that there is limited high-quality research to determine whether the procedure is effective or safe.

A new Cochrane Review was published in February 2024 comparing the LipiFlow system to other dry eye disease treatments. The authors concluded that the best available evidence was deemed to have a high level of bias, leading to low or very low certainty evidence. Additional research with adequate masking, a standardized testing methodology, and a sample representative of the meibomian gland dysfunction population is therefore needed before any firm conclusions can be drawn regarding comparative benefits and harms.

The American Academy of Ophthalmology published a Preferred Practice Pattern guideline on dry eye syndrome in 2018. This guideline suggests that thermal pulsation therapy and intense pulsed light be considered as second-line therapy in managing dry eye syndrome after a trial of more conservative step 1 therapy (lid hygiene, dietary/environmental modification, removal of offending agents, patient education, addition of ocular lubricants) proved to be inadequate. Other therapies listed under step 2 therapy measures include ocular lubricants, tea tree oil, tear conservation, or prescription drug management. This Preferred Practice Pattern was updated in 2023 and published in early 2024. The stance on thermal pulsation devices remained unchanged, suggesting it should be considered as step 2 therapy if more conservative step 1 options are inadequate. Comment on intense pulsed light was removed from this practice pattern.

Regulatory status

In 2011, the LipiFlow^® Thermal Pulsation System (TearScience; assigned the generic name of eyelid thermal pulsation system) was cleared by the U.S. Food and Drug Administration (FDA). FDA classified the LipiFlow^® System as class II (special controls) to provide a reasonable assurance of safety and effectiveness of the device. The LipiFlow^® System was identified by FDA as an electrically powered device intended for use in the application of localized heat and pressure therapy to the eyelids. The device is used in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye. FDA product code: ORZ.

Near-infrared dual imaging high definition meibography

Near-infrared dual imaging uses a patented technique that takes high-definition images of the glands using a transilluminator and near-infrared technology. LipiScan Dynamic Meibomian Imager (Johnson & Johnson Vision) its predecessor (LipiView, TearScience) has a transilluminator, which everts the eyelid and uses a proprietary infrared light source to image the lid.

The device is described as an office screening tool to identify patients with meibomian gland dysfunction. It also is listed as useful in the screening of both refractive surgery and cataract surgery candidates to identify coexisting meibomian gland dysfunction that can lead to dry eye. It may be used as a tool to determine treatment expectations.

Eyelid thermal pulsation systems (FDA product code: ORZ) cleared by the U.S. Food and Drug Administration (FDA) are summarized in Table 1.

Table 1. Eyelid thermal pulsation systems cleared by the FDA

*Other 501(k) numbers are associated with more recent versions of the device.

^aAlcon, a division of Novartis, acquired Tear Film Innovations in 2018.

Fundamento

Summary of evidence

(MGD) who receive eyelid thermal pulsation, the evidence includes systematic reviews, randomized controlled trials (RCTs), and observational studies. Relevant outcomes are symptoms, morbid events, and functional outcomes. A 2024 Cochrane meta-analysis evaluated the LipiFlow system's efficacy and safety for dry eye disease through 13 randomized controlled trials (RCTs) with 1155 participants. The findings showed that LipiFlow was comparable to other treatments like warm compresses, thermostatic devices, prescription eye drops, and doxycycline, with no notable differences in symptoms or signs. However, the evidence was deemed of low to very low certainty due to a high risk of bias. Similarly, another systematic review commissioned by the American Academy of Ophthalmology revealed that thermal pulsation with LipiFlow was more effective for meibomian gland dysfunction (MGD) and dry eye than conventional therapies such as warm compresses or eyelid hygiene. However, the review also highlighted some limitations, particularly concerning the treatment's long-term durability. Since the publication of systematic reviews, two industry-sponsored RCTs examining eyelid thermal pulsation for dry eye syndrome have been published. A randomized, assessor-masked trial comparing the efficacy and safety of LipiFlow versus thermo-mechanical action was conducted in participants with MGD across five US centers. The study involved 106 participants with primary efficacy outcomes assessed at baseline, 4 weeks, and 12 weeks post-treatment. Results showed significant TBUT improvements in both groups, with thermo-mechanical action proving non-inferior to LipiFlow , and no device-related adverse events were reported. A second randomized, assessor-masked controlled superiority trial was conducted to compare the TearCare thermal pulsation system with topical cyclosporine 0.05% (CsA) in 345 participants across 19 clinics in 11 US states. The trial found significant TBUT improvements in both groups, with TearCare showing greater enhancement, and notable OSDI improvements without significant differences between treatments. Both therapies were safe, with mild to moderate treatment-related adverse events occurring in a small proportion of participants. Observational studies on LipiFlow have shown sustained treatment effects for most outcomes up to 3 years. Additional RCTs are needed before any definitive conclusions can be drawn about the comparative benefits and risks of eyelid thermal pulsation therapy. These trials should include adequate masking, standardized testing methodologies, and longer follow-up periods. This will help ensure that the results are reliable and applicable to a broader population. Las pruebas son insuficientes para determinar que la tecnología da lugar a una mejora en el resultado neto para la salud.

Definiciones

N/D

Exención de responsabilidad

Las políticas médicas de Capital Blue Cross se utilizan para determinar la cobertura de tecnologías, procedimientos, equipos y servicios médicos específicos. Estas políticas médicas no constituyen asesoramiento médico y están sujetas a cambios según lo exija la ley o las pruebas clínicas aplicables de las directrices de tratamiento independientes. Los proveedores que brindan tratamiento son individualmente responsables de los consejos médicos y el tratamiento de los miembros. Estas pólizas no son una garantía de cobertura o pago. El pago de las reclamaciones está sujeto a la determinación del programa de beneficios del miembro y la elegibilidad en la fecha del servicio, y a la determinación de que los servicios son médicamente necesarios y apropiados. El procesamiento final de una reclamación se basa en los términos del contrato que se aplican al programa de beneficios de los miembros, incluidas las limitaciones y exclusiones de beneficios. Si un proveedor o miembro tiene alguna pregunta sobre esta política médica, debe comunicarse con Servicios para proveedores o Servicios para miembros de Capital Blue Cross.

Información de codificación

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. La identificación de un código en esta sección no denota cobertura, ya que la cobertura está determinada por los términos de la información de beneficios del miembro. Además, no todos los servicios cubiertos son elegibles para un reembolso por separado.

Investigational; therefore, not covered:

Referencias

1. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. Julio de 2017; 15(3): 334-365. PMID 28736336
2. Farrand KF, Fridman M, Stillman IO, et al. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. Oct 2017; 182: 90-98. PMID 28705660
3. Blepharitis. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. San Francisco, CA: American Academy of Ophthalmology; 2018
4. McCann P, Abraham AG, Mukhopadhyay A, et al. Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States: A systematic review and meta-analysis. JAMA Ophthalmol. Dec 01 2022; 140(12): 1181-1192. PMID 36301551
5. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. Mar 30 2011; 52(4): 1922-1929. PMID 21450913
6. Blackie CA, Korb DR, Knop E, et al. Nonobvious obstructive meibomian gland dysfunction. Cornea. Dec 2010; 29(12): 1333-45. PMID 20847669
7. Dry Eye Syndrome. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. San Francisco, CA: American Academy of Ophthalmology; 2018
8. Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. Jan 2010; 128(1): 94-101. PMID 20065224
9. Ngo W, Situ P, Keir N, et al. Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. Cornea. Sep 2013; 32(9): 1240-1245. PMID 23846405
10. Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. Mar 2011; 52(4): 2006-2049. PMID 21450918
11. Pucker AD, Tiwari R, Rueff E, et al. LipiFlow for the treatment of dry eye disease. Cochrane Database Syst Rev. Febrero de 05 2024; 2(2): CD015448. PMID 38314898
12. Tao JP, Shen JF, Aakalu VK, et al. Thermal pulsation in the management of meibomian gland dysfunction and dry eye: A report by the American Academy of Ophthalmology. Ophthalmology. Dec 2023; 130(12): 1336-1341. PMID 37642619
13. Sadri E, Verachtert A, Parkhurst GD, et al. Effectiveness and safety of a thermomechanical action device versus thermal pulsation device in the treatment of meibomian gland dysfunction. J Cataract Refract Surg. Dec 16 2024. PMID 39680541
14. Ayres BD, Bloomenthal R, Loh A, et al. A randomized, controlled trial comparing TearCare^® and Cyclosporine Ophthalmic Emulsion for the treatment of dry eye disease (SAHARA). Clin Ophthalmol. 2023; 17: 3925-3940. PMID 38143559
15. Greiner JV. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. Aug 2013; 41(6): 524-30. PMID 23145471
16. Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow^®, for the treatment of meibomian gland dysfunction. Cornea. Abril de 2012; 31(4): 396-404. PMID 22222996
17. Food and Drug Administration. 510(k) Premarket Notification.
18. Finis D, Hayajneh J, König C, et al. Evaluation of an automated thermodynamic treatment (LipiFlow^®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf. Apr 2014; 12(2): 146-54. PMID 24725326
19. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016; 10: 1385-96. PMID 27555745
20. Tauber J. A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea. Abril de 2020; 39(4): 403-407. PMID 31895884
21. Zhao Y, Veerappan A, Yeo S, et al. Clinical trial of thermal pulsation (LipiFlow^®) in meibomian gland dysfunction with pretreatment meibography. Eye Contact Lens. Nov 2016; 42(6): 339-346. PMID 26825281
22. Greiner JV. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. Aug 2013; 41(6): 524-30. PMID 23145471
23. Ophthalmology. Aug 2013; 41(6): 524-30. PMID 23145471
24. Finis D, König C, Hayajneh J, et al. Six-month effects of a thermodynamic treatment for meibomian gland dysfunction and implications of meibomian gland atrophy. Cornea. Dec 2014; 33(12): 1265-70. PMID 25321941
25. Greiner JV. Long-term (3 year) effects of a single thermal pulsation system treatment on meibomian gland function and dry eye symptoms. Eye Contact Lens. Mar 2016; 42(2): 99-107. PMID 26222095
26. Hura A, Asp P, Petropoulos AT, Czyz CN, et al. Visible meibomian gland structure increases after vectored thermal pulsation treatment in dry eye disease patients with meibomian gland dysfunction. Clin Ophthalmol. 2020; 14: 4287-4296. PMID 33324034
27. March de Ribot F, Yen M, T. Bunya VY, K. Bartlett A. (2021, October 25). Intense pulsed light (IPL) therapy. EyeWiki.
28. Tang Y, Liu R, Tu P, Song W, Qiao J, Yan X, Rong B. A retrospective study of treatment outcomes and prognostic factors of intense pulsed light therapy combined with meibomian gland expression in patients with meibomian gland dysfunction. Eye Contact Lens. 2021; 47(1): 38-44. doi:10.1097/ICL.0000000000000744. PMID 32282398; PMCID: PMC7752209
29. TearScience. LipiFlow^® thermal pulsation system. Johnson & Johnson Vision. (2021, November 12).
30. Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, Varu DM, Musch DC, Dunn SP, Mah FS. Dry eye syndrome preferred practice pattern^®. Ophthalmology. 2016; 123(1): 287-334.
31. Rong B, Tang Y, Tu P, Liu R, Qiao J, Song W, Toyos R, Yan X. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomed Laser Surg. 2018; 36(6): 326-332. doi:10.1089/pho.2017.4402. PMID 29688838
32. Liu R, Rong B, Tu P, Tang Y, Song W, Toyos R, Yan X. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017 Nov; 183: 81-90. doi:10.1016/j.ajo.2017.08.021. PMID 28887117
33. Murtaza F, Toameh D, Al-Habib S, Miani R, Chiu H, Tam E, Somani S. Safety and efficacy of broadband intense pulsed light therapy for dry eye disease with meibomian gland dysfunction. Clin Ophthalmol (Auckland, N.Z.). 2021; 15: 3983-3991.
34. Standard management options for rosacea, part 2: options according to subtype. Odom R, Dahl M, Dover J, et al. National Rosacea Society Expert Committee on the classification and staging of rosacea. Cutis. 2009; 84: 97-104.
35. Hu J, Zhu S, Liu X. Efficacy and safety of a vectored thermal pulsation system (LipiFlow^®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2022 Jan; 260(1): 25-39. doi:10.1007/s00417-021-05363-1. Epub 2021 Aug 10. PMID 34374808
36. Suwal A, Hao J, Zhou D, Du L, Xu F, Suwal R, Lu C, Wu C. Use of intense pulsed light to mitigate meibomian gland dysfunction for dry eye disease. Int J Med Sci. 2020; 17(10): 1385-1392.
37. Côté S, Zhang AC, Ahmadzai V, Maleken A, Li C, Oppedisano J, Nair K, Busija L, Downie LE. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020; 3(3): CD013559.
38. Margo JA. Thermal pulsation treatment significantly improves dry eye disease. American Academy of Ophthalmology. 2022.
39. Dry eye syndrome. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. San Francisco, CA: American Academy of Ophthalmology; 2023.
40. Miao S, Yan R, Jia Y, Pan Z. Effect of intense pulsed light therapy in dry eye disease caused by meibomian gland dysfunction: a systematic review and meta-analysis. Eye Contact Lens. 2022; 48(10): 424-429. doi:10.1097/ICL.0000000000000934